Although non-canonically Ser-phosphorylated EphA2 (pS-EphA2) has been implicated in malignant progression, including cancer cell motility, epithelial-to-mesenchymal transition (EMT), the maintenance of stemness properties, and drug resistance, its activation mechanisms have not yet been elucidated in detail (3, 7, 8, 9, 10). This evidence concerns the gene EPHA2 and cancer.